Wait-and-scan strategy feasible for head, neck paraganglioma

July 17, 2017

(HealthDay)—A wait-and-scan strategy seems to be feasible for patients with head and neck paraganglioma (PGL), according to a study published online July 10 in Head & Neck.

Thijs T.G. Jansen, from the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a involving patients with head and neck PGL. The authors measured tumor growth in axial plane diameter and volume during a wait-and-scan period.

The researchers found that 44 percent of 59 jugulotympanic tumors, 71 carotid body tumors, and 29 vagal body tumors were growing (median growth rates, 0.41, 1.6, and 1.6 mm/year, respectively). There was a significant correlation for growth with age at presentation (odds ratio, 0.974; P < 0.05). Twenty complications were induced by 17 tumors; six of these were growing, and the rates were higher than in non-complication-inducing tumors (P = 0.016).

"The results of this study illustrate that a wait-and-scan policy is a feasible treatment option in cases for head and PGL, as it potentially prevents treatment-induced morbidity in the majority of patients, including those presenting larger tumors," the authors write. "Our results also suggest that radiological follow-up is not an optimal management strategy, because a large group of tumors were found not to grow, although they did elicit complications, in the main, years after the initial diagnosis."

Explore further: Report describes primary clear cell sarcoma of head, neck

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Report describes primary clear cell sarcoma of head, neck

June 13, 2016
(HealthDay)—Three cases of primary clear cell sarcoma of the head and neck have been described in three male patients, according to a review published online June 6 in the Journal of Cutaneous Pathology.

Reduced cancer-independent life expectancy in head, neck cancer

June 27, 2017
(HealthDay)—Patients with head and neck cancer have reduced life expectancy, independent of cancer, according to a study published online June 22 in Head & Neck.

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA

February 15, 2017
(HealthDay)—For patients with human papillomavirus (HPV)-positive oropharyngeal cancer, active smokers and those with T4 tumors have increased rates of distant metastases, according to a study published online Feb. 11 in ...

More side effects with CRT plus metformin in head, neck cancer

May 7, 2017
(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.